3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
247
Lymphoma
127
Leukemia, Myeloid, Acute
103
Lymphoma, Non-Hodgkin
98
Precursor Cell Lymphoblastic Leukemia-Lymphoma
93
Neoplasms, Plasma Cell
91
Myelodysplastic Syndromes
90
Leukemia
79
Hodgkin Disease
78
Lymphoma, Large B-Cell, Diffuse
66
Leukemia, Lymphocytic, Chronic, B-Cell
65
Lymphoma, Mantle-Cell
59
Lymphoma, Follicular
57
Neuroblastoma
44
Burkitt Lymphoma
44
Lymphoma, Large-Cell, Immunoblastic
40
Lymphoma, B-Cell, Marginal Zone
37
Recurrence
34
Myeloproliferative Disorders
32
Hematologic Neoplasms
31
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
30
Immunoglobulin Light-chain Amyloidosis
29
Leukemia, Myeloid, Accelerated Phase
25
Leukemia, Myeloid, Chronic-Phase
24
Congenital Abnormalities
24
Leukemia, Myelomonocytic, Chronic
23
Graft vs Host Disease
23
Dendritic Cell Sarcoma, Interdigitating
21
Waldenstrom Macroglobulinemia
20
Anemia, Refractory, with Excess of Blasts
20
Interventions
Lenalidomide
4
Gemcitabine
4
Dexamethasone
4
Cyclophosphamide
4
Bortezomib
4
Nivolumab
3
Cisplatin
3
Carboplatin
3
vandetanib
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
2
pomalidomide
2
pembrolizumab
2
liposomal doxorubicin
2
fludarabine
2
durvalumab
2
capivasertib
2
Paclitaxel
2
Doxorubicin
2
Bevacizumab
2
venetoclax
1
umbralisib
1
ublituximab
1
tremelimumab
1
tivozanib
1
ricolinostat
1
regorafenib
1
pazopanib
1
niraparib
1
nilotinib
1
neratinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Disease Progression
×
Melphalan
×
Clear all
NCT02043847
2024-11-13
BMT-03
University of Illinois at Chicago
Phase 1
Completed
12 enrolled
12 charts